Key statistics
On Tuesday, Can Fite Biopharma Ltd (CANF:TLV) closed at 670.00, 19.64% above the 52 week low of 560.00 set on Jan 05, 2026.
52-week range
| Open | 674.80 |
|---|---|
| High | 683.00 |
| Low | 651.10 |
| Bid | -- |
| Offer | -- |
| Previous close | 683.00 |
| Average volume | 12.94k |
|---|---|
| Shares outstanding | 2.62m |
| Free float | 2.62m |
| P/E (TTM) | -- |
| Market cap | 17.50m ILS |
| EPS (TTM) | -26.94 ILS |
Data delayed at least 20 minutes, as of Feb 10 2026 15:24 GMT.
More ▼
- Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
- Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
- Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
- Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
- Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
- Can-Fite Provides Update on Clinical and Financial Status
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
- Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
- Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
- Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
More ▼
